OMEROS CORP
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a)None.
(b)None.
(c) Our directors and Section 16 reporting officers may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). During the three months ended June 30, 2024, the following 10b5-1 Plans were adopted:
| ● | On June 14, 2024, Thomas J. Cable, a member of our Board of Directors, adopted a 10b5-1 Plan providing for the potential exercise of vested stock options and the associated sale of up to 27,500 shares of our common stock under certain conditions. Mr. Cable’s 10b5-1 Plan will remain in effect until the earliest of (i) June 12, 2026, (ii) the date on which all of the shares of common stock covered by the 10b5-1 Plan have been sold, and (iii) such time as Mr. Cable’s 10b5-1 Plan is otherwise terminated or expires according to its terms. |
| ● | On June 27, 2024, Gregory A. Demopulos, M.D., our President, Chief Executive Officer and Chairman of the Board of Directors, adopted a 10b5-1 Plan providing for the potential exercise of vested stock options for 449,999 shares of our common stock, and the associated sale of up to all or a portion of the underlying shares under certain conditions. Dr. Demopulos’ 10b5-1 Plan will remain in effect until the earliest of (i) October 29, 2024 (which is the expiration date of the stock options covered by the 10b5-1 Plan), (ii) the date on which all of the shares of common stock covered by the 10b5-1 Plan have been sold, and (iii) such time as Dr. Demopulos’ 10b5-1 Plan is otherwise terminated or expires according to its terms. |
No other directors or Section 16 reporting officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5*-1(c) under the Exchange Act or any “non-Rule 10b5-*1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) during the three months ended June 30, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.